Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
4-FMA is considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. Compulsive redosing has been reported as a notable cognitive effect.
Cravings and withdrawal effects may occur if chronic users suddenly stop usage, though specific physical withdrawal symptoms have not been characterized in the available literature.
The LD50 of 4-FMA is unknown. The exact toxic dosage has not been studied in any scientific context due to the substance's limited history of human use.
4-FMA is reported to produce more cardiovascular side effects than similar fluorinated amphetamines; serious cardio- and cerebrovascular complications have been documented including arrhythmias, conduction disturbances, and acute cardiac failure, typically in the context of higher doses or pre-existing cardiovascular conditions.
4-FMA may produce damage to the brain and carries increased risks for neurotoxicity; however, the actual extent of this risk and whether it causes long-lasting serotonin depletion like some related compounds remains unstudied.
4-FMA is particularly caustic compared to other compounds and can cause chemical burns within the nasal passage and throat when insufflated.
Abuse of amphetamine-class compounds at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Approximately 5-15% of users who develop stimulant psychosis fail to recover completely. Psychosis very rarely arises from occasional or therapeutic use patterns.
4-Fluoromethamphetamine first emerged in documented form when it was detected in legal high products sold in Japanese markets in 2006. Japan subsequently moved to regulate the compound in 2008, prohibiting its sale and possession with intent to distribute while stopping short of criminalizing…
Prohibited substance under the Poisons Standard. Defined as a substance which may be abused or misused, where manufacture, possession, sale or use should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of health authorities.
Controlled since 1996 as an analogue of methamphetamine. Falls under the Controlled Drugs and Substances Act with associated criminal penalties for possession, trafficking, and production.
Listed in the government decree on narcotic substances, preparations and plants. Possession and distribution are illegal under Finnish narcotics law.
Controlled under Schedule II of the Betäubungsmittelgesetz (Narcotics Act) since July 26, 2012. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
First detected in legal highs sold in 2006. Since 2008, illegal to sell or possess with intent to distribute, though simple possession for personal use is not criminalized.
Specifically named as a controlled substance under Verzeichnis E of the Swiss narcotics regulations. Unauthorized handling is prohibited.
Not specifically scheduled at the federal level. However, as a structural analogue of methamphetamine, sale or possession could be prosecuted under the Federal Analogue Act when intended for human consumption.
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
Designated a controlled substance as of October 2015 under national drug control legislation.
As of December 2024, not specifically listed in controlled substance schedules. Exists in a legal grey area where possession may be permitted but regulatory status remains ambiguous.
Listed as a Schedule I controlled substance under Italian drug legislation. Production, sale, and possession are prohibited.
Controlled as an amphetamine analogue under the Misuse of Drugs Act. Schedule 3 substances carry penalties for possession, supply, and manufacture.
Controlled under the Misuse of Drugs Act 1971, added through the 1977 amendment covering fluorinated amphetamine derivatives. Class A designation carries the most severe penalties including up to 7 years imprisonment for possession.
9 sources cited